KDR and medullary thyroid gland carcinoma: Multikinase inhibitors (MKIs) targeting the vascular endothelial growth factor (VEGFR) were first approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of advanced/metastatic TC [medullary TC (MTC) and non-MTC] in 2013.